Mumbai, June 13, 2018: Pharma major, Alembic Pharmaceuticals has received approval from the United States Food and Drug Administration (USFDA) for its abbreviated new drug application (ANDA) for Bupropion Hydrochloride tablets USP 75 mg and 100 mg.
The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD) Wellbutrin tablets of GlaxoSmithKline LLC.
Bupropion Hydrochloride tablets USP 75 mg and 100 mg is indicated for the treatment of major depressive disorder.
Bupropion Hydrochloride tablets USP 75 mg and 100 mg have an estimated market size of USD37 million for 12 months ending December 2017 according to IMS.
The company now has 72 ANDA approvals from the USFDA.
United News of India
- This specialized division empowers patients with neurological disorders to reclaim their mobility through a…
SSI Mantra Robotic System performs a successful urology procedure on a one-year-old infant with a…
Ghaziabad, April 22, 2024: In order to strengthen the safety and wellbeing of people, Manipal Hospital…
DKMS EMPHASIZES ITS COMMITMENT TO BLOOD CANCER RESEARCH, SUPPORTS YOUNG SCIENTISTS, AND RECOGNIZES OUTSTANDING RESEARCH…
Dr. Reddy's has launched Nerivio® in Germany through its step-down subsidiary betapharm To be followed…
Hyderabad, April 13, 2024: Ankura Hospital for Women and Children is proud to announce a remarkable medical…